Shares of CRISPR genome-editing firm Caribou fell 62% after announcing workforce reductions and pausing trials for two allogeneic CAR-T therapies. The company's staff numbered 97 people as of February 27.
Shares of CRISPR genome-editing firm Caribou fell 62% after announcing workforce reductions and pausing trials for two allogeneic CAR-T therapies. The company's staff numbered 97 people as of February 27.